Abstract:Background Luteinizing hormone-releasing hormone receptor (LHRHr) represents a promising therapeutic target for treating sex hormone-dependent tumors. We coupled cecropin B, an antimicrobial peptide, to LHRH’, a form of LHRH modified at carboxyl-terminal residues 4–10, which binds to LHRHr without interfering with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This study aimed to assess the antitumor effects of cecropin B-LHRH’ (CB-LHRH’) in drug-resistant ovarian and endometrial cancers. Methods To evaluate the antitumor effects of CB-LHRH’, three drug resistant ovarian cancer cell lines (SKOV-3, ES-2, NIH:OVCAR-3) and an endometrial cancer cell line (HEC-1A) were treated with CB-LHRH’. Cell morphology changes were assessed using inverted and electron microscopes. In addition, cell growth and cell cytotoxicity were measured by MTT assay and LDH release, respectively. In addition, hemolysis was measured. Furthermore, radioligand receptor binding, hypersensitization and minimal inhibitory concentrations (against Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, and Acinetobacter baumannii ) were determined. Finally, the impact on tumor growth in BALB/c-nu mice was assessed in an ES-2 xenograft model. Results CB-LHRH’ bound LHRHr with high-affinity (dissociation constant, Kd = 0.252 ± 0.061nM). Interestingly, CB-LHRH’ significantly inhibited the cell viability of SKOV-3, ES-2, NIH:OVCAR-3 and HEC-1A, but not that of normal eukaryotic cells. CB-LHRH’ was active against bacteria at micromolar concentrations, and caused no hypersensitivity in guinea pigs. Furthermore, CB-LHRH’ inhibited tumor growth with a 23.8 and 20.4 % reduction in tumor weight at 50 and 25 mg/kg.d, respectively. Conclusions CB-LHRH’ is a candidate for targeted chemotherapy against ovarian and endometrial cancers.

Synthesis and in vitro anti-cancer evaluation of luteinizing hormone-releasing hormone-conjugated peptide

Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Furan-Conjugated Tripeptides as Potent Antitumor Drugs

Development of a Lytic Peptide Derived from BH3-only Proteins

Small peptides elicit anti-tumor effects in CT26 model through blocking PD-L1/PD-1 (TUM2P.900)

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

Synthesis and biological evaluation of bis-chalcone conjugates containing lysine linker as potential anticancer agents

A HCBP1 Peptide Conjugated Ruthenium Complex for Targeted Therapy of Hepatoma.

Modulating Protein Protein Interactions in Vivo Via Peptide-Lanthanide-Derived Nanoparticles for Hazard-Free Cancer Therapy

A Litopenaeus vannamei Hemocyanin-Derived Antimicrobial Peptide (Peptide B11) Attenuates Cancer Cells’ Proliferation

Design, Synthesis, and Antitumor Activity Study of All-Hydrocarbon-Stapled B1-Leu Peptides

Application of reproductive hormone peptides for tumor targeting.

Improved Breast Cancer Cell-Specific Intracellular Drug Delivery and Therapeutic Efficacy by Coupling Decoration with Cell Penetrating Peptide and SP90 Peptide.

Synthetic Peptides with Genetic‐Codon‐Tailored Affinity for Assembling Tetraspanin CD81 at Cell Interfaces and Inhibiting Cancer Metastasis

Targeting of Hepatoma Cell and Suppression of Tumor Growth by A Novel 12mer Peptide Fused to Superantigen Tsst-1

Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide

\Development of sulfonium tethered peptides conjugated with HDAC inhibitor to improve selective toxicity for cancer cells

A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer

Design and synthesis of TH19P01-Camptothecin based hybrid peptides inducing effective anticancer responses on sortilin positive cancer cells

Branched -helical peptides enhanced antitumor efficacy and selectivity